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 Abstract 
  Background/Aims:  Data from studies comparing the effect of hemodiafiltration (HDF) and con-
ventional hemodialysis (HD) on clinically important outcomes are insufficient to support supe-
riority of HDF. None of these studies has been participant-blinded.   Methods:   We performed a 
prospective, randomized, and patient-blinded cross-over study. Twenty patients on chronic HD 
received either HD for 2 months followed by post-dilution HDF for 2 months or in opposite or-
der. A range of clinical parameters, as well as markers of inflammation, oxidative stress and iron 
metabolism was measured.   Results:   The two treatments were similar with respect to dialysis-
related complications, quality of life, and the biomarkers of oxidative stress and inflammation. 
Compared to HD, 25-hepcidin and     2 -microglobulin were 38 and 32%, respectively, lower after 
60 days of HDF (p   !   0.001 and p   !   0.01, respectively). The consumption of ESA (erythropoietin-
stimulating agent) and LMWH (low-molecular-weight heparin) was significantly higher with 
HDF.   Conclusion:   In short term, HDF is not superior to HD regarding dialysis-related complica-
tions. The higher ESA consumption observed with HDF can be explained by blood clotting in 
tubing and dialyzers, as more anticoagulation was needed with post-dilution HDF. In a longer 
perspective, lowering serum hepcidin levels may improve pathological iron homeostasis. 
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 Introduction 
  Healthy human kidneys efficiently filter waste products over a wide range of molecular 
masses (up to 40–60 kDa). On the other hand, with conventional hemodialysis (HD) treat-
ment, only low-molecular-weight substances ( ! 500 Da) are effectively cleared while middle-
molecular-weight substances (  1  500 Da) are ineffectively removed. Consequently, these sub-
stances, many of which are putative uremic toxins  [1] , can accumulate and further add to the 
uremic burden. As a result, these patients are chronically loaded with diverse uremic toxins, 
which somehow lead to the various complications of uremia, including severe cardiovascular 
disease   [1–3]  . To increase the clearance of medium-sized molecules, a high permeability 
membrane has been developed, permitting increased hemofiltration and thereby enhanced 
solute clearance by convection   [4]  . In 1975, hemodiafiltration (HDF) was introduced. This 
method combined the convective clearance of hemofiltration and the diffusive clearance of 
HD, resulting in improved clearance of middle-molecular-weight substances  [5] . The limita-
tion of this technique was the huge volumes of replacement solution required, a problem that 
was overcome by the development of HD machines that performed HDF with on-line pro-
duction of replacement fluid   [6]  . This dialysis modality was found to be clinically safe, and 
optimism was evoked that HDF would provide more efficient treatment that could reduce 
the high morbidity in the uremic population. However, according to a Cochrane meta-anal-
ysis, evidence showing that HDF is superior to conventional HD is lacking   [7]  . In the same 
report, it is noted that no randomized study comparing HD and HDF has blinded the par-
ticipants or investigators to the intervention.
    The aim of this study was to perform a patient-blinded and partially investigator-blind-
ed comparison between HD and HDF regarding a wide variety of clinical parameters, such 
as dialysis-related symptoms, dialysis complications and quality of life as well as consump-
tion of LMWH (low-molecular-weight heparin) and ESA (erythropoietin-stimulating agent). 
In addition, we wanted to evaluate possible differences in various clinical laboratory param-
eters, in levels of serum markers of oxidative stress and inflammation as well as in clearance 
of selected middle-molecular-weight substances.
  Subjects  and  Methods 
 Patients 
  Patients on regular HD treatment at the Hemodialysis Unit Mölndal, Sahlgrenska Uni-
versity Hospital, in Gothenburg, Sweden, were screened for inclusion in the study. The inclu-
sion criteria were age   1  18 years and at least 3 months on HD treatment with either HD or 
HDF. Additionally, all patients had to be in clinically stable condition, without any signs of 
acute inflammation, infection or cardiovascular disease. Twenty patients were included, and 
5 additional patients were recruited to replace dropouts that discontinued the study for var-
ious reasons. Two patients were withdrawn during the HD period, 1 because of severe pain 
caused by peripheral ischemia and 1 patient died. During the HDF period, 1 patient got an 
intracerebral bleeding without previous severe hypertension, and 1 patient requested exclu-
sion due to severe hypertension which developed at onset of HDF. Finally, 1 patient was re-
moved because of severe dialysis access problems.
  The  mean   8   SD age of the participants was 60.6   8   13.6 years and the gender distribu-
tion was set to 70% males (male/female 14/6) since this reflects the distribution in the Swed-
ish HD population   [8]  . The causes of renal failure were diabetic nephropathy (7 patients), 
chronic glomerulonephritis (4 patients), nephrosclerosis (4 patients), adult polycystic kidney 
disease (2 patients), and chronic interstitial nephritis (3 patients). The dialysis modality be-57
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fore inclusion was HD in 15 patients and HDF in 5 patients. Twelve patients had central
venous dialysis catheter and 8 had AV fistula, and the dry weight at inclusion was 78.9   8  
15.1 kg.
  Study  Design 
 This study is a single-center, prospective, and randomized crossover comparison of post-
dilution HDF and low-flux HD. The local ethics committee approved the study protocol, and 
informed consent was obtained from all subjects. 
    After inclusion, 20 patients were randomized to receive either HD or HDF for 60 days. 
Thereafter, they were switched to the other dialysis modality for the same period of time. 
The study was patient-blinded and partially investigator-blinded; the interviewers did not 
know which treatment was performed (see below). Study visits, with interviews and blood 
sample collection, were performed at baseline and on day 60 of the respective dialysis mo-
dality. 
  Blood  Pressure  Measurements 
  Blood pressure measurements were standardized. Only one type of automatic blood 
pressure equipment was used (Gambro BP 100). The pressure was measured in the same arm 
before and after each dialysis treatment, both supine after 10 min rest and in upright posi-
tion, without delay. The average blood pressure at the three last dialysis sessions in each treat-
ment period was used to compare blood pressure levels between the dialysis modalities. 
Blood pressure medications were altered as needed during the study and all changes were 
recorded.
    Questionnaires Concerning Dialysis-Related Symptoms and Quality of Life 
  All interviews were double-blinded. This could be achieved because our dialysis clinic 
is split into two spatially distinct units with different dialysis staff, and all interviews were 
performed by nurses from the other team. At the interviews, patients answered health-relat-
ed questions in two separate questionnaires. The first one was the Swedish version of the 
standardized quality of life questionnaire, IQOLA SF-36   [9]  . The second one was generated 
by the study designers and specifically concerned 12 symptoms and health-related condi-
tions occurring during the previous 4 weeks. The patients were asked to specify if symptoms 
appeared before, during or after the dialysis treatment. If appropriate, they were asked if the 
symptom or condition occurred after dialysis, during the night or during the following day. 
The results were registered on a visual analogue scale from 1 to 10.
    Blood Sampling and Analyses 
 All blood samples were collected from the arterial line. Analysis on pre-dialysis, routine 
tests, were performed without delay, while post-dialysis serum samples were centrifuged and 
stored at –80    °    C. The dialysis adequacy was evaluated by calculation of spKt/V according to 
Daugirdas   [10]  , and samples for measurements of post-dialysis urea were drawn 2 min after 
the dialysis treatment. All routine serum analyses, as well as high sensitivity CRP, were per-
formed at our local hospital laboratory. LDL oxidation was estimated by measuring the base-
line level of diene conjugation in lipid-extracted plasma LDL   [11]  . The plasma total antioxi-
dant capacity was assessed by a slightly modified TEA C method (TROLO X Equivalent
Antioxidant Capacity)   [12]  . Oxidation of proteins was determined by measuring protein
carbonyl content with a spectrophotometric carbonyl assay  [13] . The serum concentration of 
IL6 and myeloperoxidase were analyzed using commercially available ELISA kits from Dia-
clone, Fleming, France and Assay Designs, Inc., Ann Arbor, Mich., USA, respectively. Serum 
25-hepcidin was measured at Hepcidinanalysis.com, Nijmegen, the Netherlands by a com-58
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bination of weak cation exchange chromatography and time-of-flight mass spectrometry 
 [14] . Because of insufficient amount of frozen serum, it was not possible to analyze s-hepcidin 
in 5 patients.
  Dialysis  Treatment 
  All treatments were carried out on AK 200 ULTRA dialysis machines (Gambro, Lund, 
Sweden) and with BL 200B blood tubing. Polyamide dialysis membranes were used in all 
treatments; low-flux (Polyflux 17 L, effective area of 1.7 m  2  ) in HD and high-flux (Polyflux 
21S, effective area of 2.1 m  2  ) in HDF. All treatments were patient-blinded; the dialysis ma-
chine was concealed behind a screen, making it impossible for the patient to identify which 
treatment was given.
  In HDF, on-line post-dilution was used, and the replacement volume was standardized 
to 25–30% of the total blood volume treated. Anticoagulation was performed with tinza-
parin sodium (Innohep    , Leo Pharma, Bellerup, Denmark). For each patient, the dialysis 
prescription was kept constant throughout the study (total dialysis time, dialysate flow = 
500 ml/min, dialysate temperature and dialysate composition) and the blood flow was kept 
as stable as possible. In patients with an A V fistula, recirculation was measured after 4 
weeks of treatment with either HD or HDF. All intradialysis symptoms and signs were reg-
istered.
    Data Collection and Statistical Analysis 
  Microsoft Excel was used to register data and generate graphs. Data are expressed as 
mean   8   SD if not otherwise indicated. To exclude carry-over effect, all data other than fre-
quency of intradialysis complications and total anticoagulation dose were only collected 
from the second month of respective treatment. Paired Student’s t test or, if appropriate, non-
parametric test (Wilcoxon) was used to compare means in respective treatments. Pearson 
correlation was used to calculate strength of association between two variables.     2   test was 
used to compare frequency of pooled symptoms between treatments and sign test was used 
to compare the frequency of a specific symptom. Differences were considered significant at 
p     !   0.05.
  R e s u l t s  
  Dialysis Efficacy and Average Dialysis Dose 
  The total number of dialysis sessions was 1,040, 520 with each treatment. The dialysis 
efficacy and average dialysis dose delivered during the study were equal between treatments. 
The dialysis data (mean  8  SD per dialysis session, HD/HDF) were as follows: treatment time 
265   8   27/267   8   28 min, Qb 312   8   32/310   8   34 ml/min, Kt/V 1.47   8   0.24/1.51   8   0.20, 
dialyzed blood volume 82.4   8   5.8/81.2   8   7.1 liter, pre-dialysis weight 80.9   8   14.1/80.6   8  
14.4 kg, post-dialysis weight 78.5  8  13.9/78.3  8  14.0 kg, ultrafiltration volume 2.4  8  1.0/2.3 
  8   1.0 liter and the replacement volume with HDF was 22.1   8   4.2 liter.
    Incidence of Intradialysis Symptoms 
  The total number of symptoms registered during treatment with HD and HDF was 
204 and 200, respectively. All symptoms were mild, and the most common (HD/HDF) 
were muscle cramps (79/60), headache (40/45), hypotension (28/32), restless legs (10/19), 
and numbness in hands and feet (10/18). None of these differences were statistically sig-
nificant.59
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  Health  Questionnaire 
  All patients answered visual analogue scale questions regarding headache, nausea, diz-
ziness, thirst, itching, muscle cramps, fatigue, restless legs, dyspnea, sleep disturbance and 
appetite. In summary, no differences between the two treatments were found.
  Quality  of  Life 
  The results of the IQOLA SF-36 questionnaire at day 60 with respective treatment are 
shown in   table 1  . With the exception of a lower score for social functioning with HDF (p   !  
0.05), there was no significant difference in quality of life between HD and HDF. 
    Arterial Blood Pressure and Body Weight 
  The arterial blood pressure was slightly higher during the last week of treatment with 
HDF compared to the same period on HD treatment (  table 2  ). This was noted in all blood 
pressure measurements, but was only statistically significant in blood pressure measured in 
upright position before dialysis (p   !   0.05). The blood pressure medication was identical dur-
ing the last week with respective treatment and the dry weight did not change during the 
study. The mean dry weight during the last week in HD and HDF was 77.1   8   15.1 and 76.8 
  8   15.4 kg, respectively.
    Pre-Dialysis Clinical Chemistry Parameters  
  The results of pre-dialysis clinical chemistry analysis at baseline, as well as on day 60 
with respective treatment, are shown in   table 3  . Compared to baseline, leukocyte count, s-
creatinine and BUN were significantly lower with HD and HDF. Compared to HD, there was 
a trend towards lower levels of both creatinine and BUN with HDF and serum albumin was 
significantly lower with HDF. Additionally,     2-microglobulin was significantly lower in 
HDF, both compared to baseline and compared to HD. Finally, compared to HD, treatment 
with HDF was associated with a trend towards lower ferritin values and higher MCV values 
on day 60 (p = 0.08 in both cases). No other significant differences between the dialysis mo-
dalities were found.
    Post-Dialysis Markers of Inflammation, Oxidative Stress and Iron Metabolism 
 The post-dialysis levels of different serum markers of inflammation and oxidative stress 
were measured after the last dialysis session in the respective study period (  table 4  ). In short, 
no differences between levels of inflammation or oxidative stress were found. On the other 
HD HDF
Physical functioning 53826 50824
Role physical 30836 26839
Bodily pain 64828 68822
General health 41821 41818
Vitality 51826 52827
Social functioning 75824 64827*
Role emotional 60841 60845
Mental health 75822 75818
Physical component summary 47814 46817
Mental component summary 65811 63810
*   p < 0.05 compared to HD.
  Table 1.    Q  uality of life on day 60 
of respective dialysis modality 
(mean   8   SD)
 60
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Table 2.   Systolic and diastolic blood pressure during the last three dialysis sessions of respective dialysis 
modality (mean 8 SD)
Pre-dialysis P ost-dialysis
HD HDF HD HDF
Systolic blood pressure, mm Hg
Supine 157.5826.1 161.2829.9 157.1822.8 161.6825.1
Standing 151.1826.1 156.4831.1 137.9818.4 143.0824.3
Diastolic blood pressure, mm Hg
Supine 86.4810.8 88.9812.6 85.3810.3 86.8812.8
Standing 86.8812.6 90.1814.0* 81.889.5 85.1813.4
* p   < 0.05 compared to HD.
Table 3.   Hematological and chemical parameters at baseline and on day 60 in the respective study period 
(mean 8 SD)
Day 0 D  ay 60
Baseline HD HDF
Hemoglobin, g/l 116.1812.2 116.188.4 115.186.0
Mean corpuscular volume (!10–15/liter) 97.185.5 97.285.7 98.084.9
Leukocyte count (!109/liter) 8.182.5 7.081.8a, ** 7.182.3a, **
Thrombocyte count (!109/liter) 241876 234869 236.5883.1
s-sodium, mmol/l 137.283.2 137.382.3 137.582.4
s-potassium, mmol/l 5.080.9 4.980.6 5.080.8
s-calcium, mmol/l 2.480.2 2.480.2 2.480.4
s-phosphate, mmol/l 2.080.5 1.880.4 1.780.4
s-bicarbonate, mmol/l 23.582.0 24.281.6 24.182.3
s-creatinine, mol/l 7488240 6888213a, ** 6718192a, **
s-BUN before dialysis, mmol/l 21.985.8 18.184.5a, ** 17.383.8a, ***
s-albumin, g/l 34.883.2 36.082.9 34.382.6b, **
s-ferritin, g/l 3028141 3118126 253895
s-hsCRP, mg/l 11.2812.2 9.8810.2 9.6811.1
s-2-microglobulin, mg/l 30.6811.9 34.6817.0 23.788.1a, b, **, ***
a C  ompared to baseline. b Compared to HD. * p < 0.05. ** p < 0.01. *** p < 0.001.
HD HDF
s-interleukin 6, pg/ml 17.4817.0 18.1811.5
s-MPO, ng/ml 90.1876.8 93.4859.9
s-protein carbonyl, nmol/l 23.584.4 23.184.3
s-BD-LDL, mol/l 44.4813.8 41.1813.3
s-TEAC, mol/l Trolox 4.080.6 4.180.7
s-hepcidin, nmol/l 11.185.4 6.982.9**
* * p < 0.01 versus HD.
Table 4.   Post-dialysis markers of 
inflammation, oxidative stress 
and iron homeostasis on day 60 
with respective treatment (mean 
8 SD)61
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hand, the level of post-dialysis hepcidin was 38% lower after treatment with HDF and it was 
correlated to corresponding pre-dialysis ferritin as seen in   figure 1   (p = 0.001 after HD and 
p = 0.17 after HDF).
    ESA, i.v. Iron and Anticoagulation Consumption  
  We calculated the individual ESA and iron consumption during the second month of 
respective treatment. Two patients did not need any ESA and the variation among the other 
18 patients was large. ESA consumption was significantly higher with HDF. The median ESA 
dose in patients that needed ESA (n = 18) was 136 IU/kg/week for HD and 163 IU/kg/week 
for HDF (p  !  0.05). Iron consumption was also higher during treatment with HDF, albeit not 
significant. The median i.v. iron dose during HD was 350 mg/month and 400 mg/month 
during HDF (n.s.). The total LMWH dose was 33.6% higher during treatment with HDF; the 
mean dose with HD was 4,876   8   1,518 IU per dialysis session, compared to 6,514   8   1,668 
IU per session with HDF (p = 0.001). Further, 4 out of 520 HDF treatments were terminated 
ahead of schedule because of coagulation in the tubing and/or dialyzer.
  Discussion 
  In this short-term, prospective, blinded, randomized trial, we compared low-flux HD 
and post-dilution HDF regarding a wide variety of clinical parameters. The major differ-
ences found were due to better clearance of middle-molecular-weight substances, such as 
    2-microglobulin and 25-hepcidin, by HDF. 
     2-microglobulin   [15]   has a molecular weight of 11,800 Da. It is normally cleared from 
plasma by glomerular filtration and accumulates in severe renal failure. With time, this can 
lead to amyloid formation and eventually amyloid depositions in soft tissues, such as joins 
and vessel walls   [16]  . Even though most of these depositions are asymptomatic with unclear 
clinical relevance   [17]  , patients receiving HD over many years can develop dialysis-related 
amyloidosis with, for example, erosive arthritis and carpal tunnel syndrome   [16]  .
  The clearance of   2-microglobulin is higher with HDF than with HD  [18–21] . However, 
the impact on lowering pre-dialysis     2-microglobulin by HDF has been moderate and often 
not significant   [20, 22]  , which probably is due a resistance to    2-microglobulin  transfer  be-
tween body compartments   [22]  . Nevertheless, we found significantly lower pre-dialysis se-
  Fig. 1.   Post-dialysis serum hepcidin values plotted against corresponding pre-dialysis serum ferritin lev-
els.   a   HD, p = 0.001.   b   HDF, p = 0.17. 62
Nephron Extra 2012;2:55–65
 DOI:  10.1159/000336482 
  Published online: March 28, 2012 
EXTRA
  Stefánsson et al.: Hemodiafiltration Improves Plasma 25-Hepcidin Levels 
www.karger.com/nne
    © 2012 S. Karger AG, Basel
rum     2-microglobulin levels with HDF. The clinical benefit of reducing    2-microglobulin 
by HDF is unclear and even though small studies indicate reduction of clinically relevant 
dialysis-related amyloidosis by convective therapies  [23]  this has yet to be confirmed in larg-
er long-term trials   [7]  .
    25-Hepcidin, a 25-amino acid peptide hormone produced by the hepatocytes, is a key 
regulator of iron homeostasis   [24]  . It binds to, and induces internalization of ferroportin, a 
transmembrane iron channel present in enterocytes, macrophages and hepatocytes   [25]  . 
Thereby, iron transport is hindered and increased hepcidin levels can lead to true iron defi-
ciency by decreasing intestinal iron absorption, and to functional iron deficiency by blocking 
iron release from iron stores. Hepcidin production is induced by inflammation and iron 
overload   [26, 27]  , two common findings in patients with chronic kidney disease. Further, 
hepcidin is eliminated by the kidneys and, indeed, patients on chronic HD treatment have 
increased serum hepcidin levels   [28, 29]  . The level of serum hepcidin correlates very well 
with the level of serum ferritin   [29–32]  , and our results are in line with these reports (  fig. 1 ).
    In the present study, post-dialysis serum hepcidin at day 60 was 38% lower in the HDF 
group compared to HD. Hepcidin is a middle-molecular-weight substance with a molecular 
weight of 2,791 Da   [33]   and is eliminated by both low- and high-flux HD   [32]  . The median 
reference level of serum hepcidin measured by mass spectroscopy is 4.2 n  M   (range 0.5–13.9) 
 [34] . In our patients, serum hepcidin was within this interval in all cases after treatment with 
HDF (median 6.9, range 2.2–12.0), whereas 31% of the patients had serum hepcidin values 
outside these limits after HD (median 10.9, range 2.6–18.9).
  The clinical benefit of lowering hepcidin levels by convective dialysis treatments remains 
to be investigated. However, patients with chronic renal failure often suffer from functional 
iron deficiency, which probably is caused by pathologically high hepcidin levels in the circu-
lation   [35]  . In this condition, transferrin saturation is low even though iron stores are high, 
and potentially toxic intravenous iron administration is necessary to maintain adequate 
erythropoiesis. In this way, a vicious circle can arise, leading to further increase in the hep-
cidin level. Therefore, it seems reasonable that efforts in lowering the level of hepcidin in 
patients with chronic renal failure will bring the iron homeostasis towards a more normal 
state. Our findings, with a trend towards lower ferritin levels and increased MCV after 2 
months of treatment with HDF, are in line with this hypothesis, indicating iron mobilization 
from the stores. This is further supported by Lin et al.  [36] , who reported lower ferritin levels 
and better iron utilization with HDF.
  Some reports indicate better hemoglobin levels and lower erythropoietin need in patients 
treated with HDF  [36–39] . However, there is not sufficient evidence to support this  [7]  and we 
did not notice any difference in the hemoglobin levels between HD and HDF. On the other 
hand, more iron and ESA were administrated during treatment with HDF. The significant 
increase in ESA dose with HDF is most likely explained by increased clotting in tubing and 
dialyzers secondarily to increased hemoconcentration with post-dilution HDF. Indeed, a 33% 
higher LMWH dose was administrated during HDF, a dose that apparently was too low.
    Our study is the first randomized participant-blinded trial comparing the frequency of 
intradialysis complications, dialysis-related symptoms and quality of life between HD and 
HDF. We found that treatment with HDF was well tolerated with the same overall frequency 
of intradialysis complications, which is in agreement with another randomized but not 
blinded study   [40]  . In particular, we did not find lower frequency of hypotension during 
HDF, which is in contrast to several reports on convective treatments  [41, 42] , but in line with 
other studies   [7, 40]  . Further, regarding dialysis-related symptoms, well-being and quality of 
life, no difference was noted between treatments, which is in line with a 12-month random-
ized study   [20]  . We cannot explain our finding of significant lower social functioning at the 
end of the HDF period. 63
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    A small elevation in arterial blood pressure has been described with convective HD 
treatment   [42]  . In line with this report, we noted a slight elevation in blood pressure during 
the last week on HDF compared to HD, albeit only significant in diastolic pressure measured 
before dialysis in upright position. The clinical relevance of this small blood pressure eleva-
tion is unclear, but it could hypothetically reflect better baroreceptor sensibility with HDF. 
No patient on HDF treatment needed additional prescription of anti-hypertensive drugs. 
However, cases with accelerated hypertension after initiation of HDF have been reported 
 [20] , and in our study 1 patient was withdrawn because of severe hypertension that occurred 
directly after HDF onset.
    High mortality and severe atherosclerosis in patients with chronic renal failure have 
been related to inflammation and increased oxidative stress. We evaluated the level of dif-
ferent post-dialysis parameters of inflammation and oxidative stress but found no difference 
between the treatments, which is in line with other studies   [38, 43]  . However, the possible 
effect of HDF on oxidative stress is an unresolved issue as studies have shown increased  [44] , 
reduced   [40, 45]   or no effect   [46]  .
  Serum phosphate is more efficiently removed by HDF compared to HD  [20, 40, 47] . Even 
though data are insufficient to conclude that HDF is superior regarding phosphate control 
 [7] , recently published data from ongoing large trial support this  [48] . We found no superior-
ity of HDF regarding phosphate control; however, the present study was not designed to spe-
cifically investigate this issue and the dose of phosphate binders was altered as needed. 
    We noticed a significant decrease in pre-dialysis serum albumin levels during HDF. 
Likely, this reflects some albumin removal by HDF, a finding that has also been observed by 
others   [45, 49]  . The clinical relevance of this is not clear. 
    In summary, our data allow us to conclude that treatment with HD and HDF is similar 
regarding intra- and interdialysis complications. We found only small differences, mainly 
secondary to increased clearance of middle-molecular-weight substances. The most interest-
ing finding was the lower level of serum hepcidin with HDF, indicating that more normal 
iron homeostasis with lower degree of functional iron deficiency could, in theory, be achieved 
by HDF. This remains to be investigated in trials of longer duration than 60 days.
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